Granules India Ltd (BSE: 532482) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹20,461 Cr, it ranks #369 by market cap among the 6,137 Indian listed companies on FinBizNet, and #17 of 86 in Medicinal Chemicals and Botanical Products. At ₹794.75 (as of 25 Oct 2026), the share price is 14.0% below its 52-week high of ₹923.65 and 50.0% above its 52-week low of ₹529.85. The share price is up 39.7% over one year and down 4.7% over three months.
| Current Price | ₹794.75 |
|---|---|
| Market Cap | ₹20,461 Cr |
| BSE Code | 532482 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 32.9 |
| Return on Equity | 13.52% |
| Return on Assets | 7.98% |
| 52-Week Range | ₹529.85 – ₹923.65 |
| 1-Year Price Change | +39.7% |
| 3-Month Price Change | -4.7% |
| Beta (1Y) | 0.29 |
| Dividend Yield | 0.22% |
| Headquarters | Hyderabad, Telangana |
| Website | www.granulesindia.com |
| Revenue | ₹1,477 Cr |
|---|---|
| Net Profit | ₹180 Cr |
| Net Margin | 12.2% |
| EPS (Basic) | ₹7.26 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating
1. Manufacture of Pharmaceuticals-This segment offers pharmaceutical products, including ingredients and intermediaries. 2. Active Pharmaceutical Ingredients (API's)-This segment engages in the production and sale of active pharmaceutical ingredients, including metformin, methocarbamol, guaifenesin, phenazopyridine, and paracetamol, or acetaminophen. 3. Pharmaceutical Formulation Intermediates (PFI's)-This segment engages in the production and sale of pharmaceutical formulation intermediates.
1. Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Granules India Ltd | ₹20,461 Cr | 32.9 | 13.52% | ₹1,477 Cr | +39.7% |
Listed by market capitalisation. Ratios are shown for context only.
Granules India Ltd is trading at ₹794.75, with a market capitalisation of ₹20,461 Cr.
Granules India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Granules India Ltd has a P/E of 32.9 and a return on equity of 13.52%.
Granules India Ltd is listed on the BSE under the scrip code 532482.
Granules India Ltd's share price is up 39.7% over one year and down 4.7% over three months. Its 52-week range is ₹529.85 to ₹923.65.
In Q1 FY27, Granules India Ltd reported revenue of ₹1,477 Cr and net profit of ₹180 Cr, with basic EPS of ₹7.26 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.